Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5–6 years

Journal of Infection and Chemotherapy(2024)10.1016/j.jiac.2024.06.011Source: DataRank Database

Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5–6 years is a research paper published in Journal of Infection and Chemotherapy (2024). On theSindex it has a DataRank of 0.165. It has been cited 2 times.

N/A

0.165DataRank · unranked

Scored on demand from live citation data

2 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.54)OA: hybridTopics (53)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (7)

Asuka Kawamura,Yoshitaka Sogawa ORCID,Sachiko Sakakibara,Takafumi Nakatsu,Motoshi Kimata

Live enrichment

PubMed:38906375 OpenAlex:https://openalex.org/W4399803428

Daiichi Sankyo Co Ltd

FWCI

0.54

Citation Percentile

0.7%

Citation Trend

2025

hybridLicense: cc-by

journalhttps://www.jiac-j.com/article/S1341-321X(24)00166-1/pdf

publisherhttps://www.jiac-j.com/article/S1341-321X(24)00166-1/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1341321X24001661?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1341321X24001661?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jiac.2024.06.011

Fields of Study

Virology and Viral DiseasesImmune responses and vaccinationsVaccine Coverage and HesitancyChildChild, PreschoolFemaleHumansMaleAntibodies, ViralEast Asian PeopleImmunization, SecondaryImmunogenicity, VaccineJapanMeaslesMeasles-Mumps-Rubella VaccineMumpsRubellaVaccination

MeSH Terms

Immunogenicity, VaccineEast Asian PeopleAntibodies, ViralChildChild, PreschoolFemaleHumansImmunization, SecondaryJapanMaleMeaslesMeasles virusMumpsMumps virusRubellaRubella virusVaccinationMeasles-Mumps-Rubella Vaccine

Keywords

MMR vaccineMeasles-Mumps-Rubella VaccineMedicineMeaslesRubellaImmunogenicityVirologyRubella vaccineMumps vaccineMeasles vaccineVaccinationPediatricsImmunologyAntigenNeutralizing antibodyRit 4385Second Mmr Vaccination

Sustainable Development Goals

SDG 0: Zero hunger

Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5–6 years

FAIR Checklist

DataRank Breakdown

Authors (7)

Funding (1 grants)

Impact

Open Access

Topics